Lumida
/WALD
⌘K
Waldencast PLC

Waldencast PLC

WALD
$1.73USD↑+2.37%+0.04 today

MARKET CAP

222.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
Buy NowMedium

WALD is in a Stage 2 advancing regime with higher highs and higher lows above rising EMAs and the 50SMA, underpinning a bullish medium-term bias. The recent pullback into the 9/21 EMA is healthy and offers a constructive entry with neutral OB/OS context and no exhaustion. However, the longer-term trend remains down, and stage transition risk into distribution at the May highs underscores the need for caution. We will engage on this pullback into EMAs support.

  • ↑FDA approved Obagi saypha ChIQ gel; 94% of injectors view it as complementary, driving dermal filler expansion.
  • ↑Divested Obagi Medical for up to $460M, earmarked for debt reduction and Milk Makeup growth.
  • ↓Profitability is weak, indicating struggles to generate sustainable returns.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Waldencast plc (NASDAQ: WALD) is an emerging player in the beauty and personal care sectors, with a strong focus on derma-cosmetic products through its brand Obagi Medical and cosmetics brand Milk Makeup. The FDA approval of its latest injectable gel reflects its positioning within the growing dermal filler market and signals its foray into the aesthetics segment. The company focuses on innovative beauty solutions while maintaining a competitive edge through strategic decisions, such as the recent sale of its Obagi Medical unit to redirect focus towards expanding its Milk Makeup brand.

Bull says

  • ↑FDA approved Obagi saypha ChIQ gel; 94% of injectors view it as complementary, driving dermal filler expansion.
  • ↑Divested Obagi Medical for up to $460M, earmarked for debt reduction and Milk Makeup growth.
  • ↑Book-to-price ratio of 1.14 suggests the stock is undervalued relative to assets.
  • ↑Manageable leverage risk supports financial flexibility post-divestiture.
  • ↑Modest dividend yield of 0.22% offers income buffer amid volatility.
  • ↑Refocus on Milk Makeup targets a high-demand cosmetics segment.

Bear says

  • ↓Profitability is weak, indicating struggles to generate sustainable returns.
  • ↓Low liquidity raises risk of cash shortfalls for near-term obligations.
  • ↓Negative earnings yield suggests overvaluation relative to earnings power.
  • ↓High short interest reflects market skepticism and downside pressure.
  • ↓Economic fluctuations may curb discretionary spending on beauty products.
  • ↓Macro uncertainty and regulatory risks could hamper sector growth.

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 05-04-2026neutral

Transcript signals

Bull points

  • During the quarter, we made strong progress against our growth strategy, elevating our powerful brands, launching breakthrough innovation, expanding points of distribution, and increasing community engagement and love while investing in support for our future.
  • We're encouraged by the end of the quarter performance, which gives us confidence that our brands and businesses are poised to achieve our annual growth and profitability goals.
  • Our strategies are working very well. We're strengthening our brands, driving industry-leading innovation, and expanding our brand's footprints so we can reach more and more consumers around the world.

Bear points

  • I think what is driving more the slowdown on the budget relative to prior years is more we don't have the tailwinds that we had on our Amazon business that we had last year.
  • Even at the highest rates, even if for some reason we went back to the extremely high rates that we saw at the beginning of the announcements on tariffs, we believe that that is quite manageable, given our relatively low exposure to China.
  • we have reported a net revenue of $65.4 million, representing a decline of 4.1% from the first quarter of last year.
Read full transcript analysis ›